Latest Cinclus Pharma News & Updates

See the latest news and media coverage for Cinclus Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Cinclus Pharma

Clinical-stage pharmaceutical company developing gastric acid disease treatments

cincluspharma.com

Headquarters: Stockholm, Sweden
Founded year: 2014
Company type: Private company
Number of employees: 10–27
Industry: Pharmaceuticals

Last updated September 28

Latest news about Cinclus Pharma

In short: Cinclus Pharma completed Phase III HEEALING1 patient visits, with topline results expected in Q4 2026.

Company announcements

August 19 Cinclus Pharma

Cinclus Pharma reports Q2 2026 financial results and HEEALING1 trial enrollment completion

The company recorded net sales of TSEK 1,766 in Q2. Phase III HEEALING1 enrollment is complete with topline results expected in Q4 2026.

August 7 Cinclus Pharma

Cinclus Pharma signs licensing agreement with Zentiva for Europe

Zentiva obtains exclusive commercialization rights for linaprazan glurate. Potential milestone payments total up to EUR 220 million plus royalties, targeting severe erosive reflux disease.

May 13 Cinclus Pharma

Cinclus Pharma presents Q1 2026 interim report

CEO Christer Ahlberg, CFO Magnus Christensen, and R&D Director Margit Mahlapuu discuss financial results.

May 13 Cinclus Pharma

Cinclus Pharma announces Q1 2026 financing and trial progress

The company secured EUR 28 million to advance Linaprazan glurate's Phase III trials, expecting top-line results in Q4 2026.

Media coverage

September 28 Finanznachrichten

Cinclus Pharma Holding AB: Cinclus Pharma has completed all patient visits in Phase III HEEALING1 study; topline results expected in Q4 2026

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company developing next-generation treatments for acid-related diseases, announced today that the last patient has completed the final...

September 1 The Globe and Mail

Cinclus Pharma Clears Key Phase III Milestone in Erosive GERD Trial

Cinclus Pharma Holding AB ( (SE:CINPHA)) has shared an announcement. Cinclus Pharma has completed the eight-week treatment period for all patients in its pivotal Phase...

June 26 Yahoo Finance

Cinclus Pharma Holding AB (CINPHA.ST) Q2 FY2025 earnings call transcript

Earnings call Cinclus Pharma reported Q2 2025 results marked by a transformative EUR 220 million European licensing deal with Zentiva, SEK 34.1 million in net...

April 22 Dagens industri

Co-founder appears to have sold everything in Cinclus Pharma - at a big discount

On Wednesday afternoon, Pareto brokered a position worth nearly 25 million kronor in Cinclus Pharma at a big discount. The share plummets 18 percent. In the newsletter Toppnyheter receives...

Never miss news about Cinclus Pharma

Track Cinclus Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Cinclus Pharma competitors & trending companies

Browse news for competitors to Cinclus Pharma and other trending companies.